FY2026 Earnings Forecast for BioSyent Issued By Bloom Burton

BioSyent Inc. (CVE:RX) – Analysts at Bloom Burton cut their FY2026 earnings per share estimates for shares of BioSyent in a research note issued on Tuesday, May 20th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.86 per share for the year, down from their prior estimate of $0.88. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.93 EPS.

BioSyent Stock Performance

RX opened at C$11.70 on Wednesday. BioSyent has a twelve month low of C$8.92 and a twelve month high of C$12.13. The company has a fifty day moving average of C$10.81 and a 200-day moving average of C$11.06. The stock has a market cap of C$133.82 million, a PE ratio of 18.99 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.